Genmab
Forbes Global 2000 1998 #1810 by revenue Denmark Healthcare Drugs & Biotechnology genmab.com
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases.
Forbes Global 2000's description, shown to identify the company. We rate the name, not the business.
- Evocativity EVOC : green
- Gen and mab clearly signal genetic antibody therapeutics to insiders
- Brevity BREV : green
- 6 letters, 2 syllables. Up to seven letters is green, eight at two syllables too; up to ten yellow, eleven or more red.
- Greppability GREP : green
- Found inside 0 other dictionary words.
- Googlability GOOG : green
- Distinctive combined biomedical roots
- Pronounceability PRON : green
- Simple gen and mab syllables
- Spellability SPEL : yellow
- Gen versus jen needs confirmation
- Verbability VERB : red
- No natural therapy-use action
- Nominology
- 88
- All seven dimensions and .com ownership, weighted as set out on Methodology.
- Fluency
- 100
- Brevity and pronounceability only: the subset with published outcome evidence behind it.
- PG grade
- 1 / 4
- Graham's own four-step ladder.
- Exact .com
- Owned
- Shape
- invented
- Length
- 6 chars, 2 syllables
- Distinctiveness
- suggestive
Watkins SCRATCH flags
- Curse-of-knowledge
Rubric version 2026.10.20-1, judged by gpt-6.1-sol (agent).
This scores the name only. See Methodology.
These judged dimensions came from an AI agent working through the judging queue in a chat, on the same rubric the scoring pipeline sends. The agent passed the calibration exam before its work was accepted, and each batch it judged hid two names with known answers as a check. The model is named as the agent reported it.